The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Merck’s (NYSE:MRK) Recarbio (imipenem/cilastatin/relebactam) for the treatment of Gram-negative infections in adults with limited treatment options.
The anti-infective will be available as a 500 mg/500 mg/250 mg powder for solution for infusion.
A final decision from the European Commission usually takes ~60 days but has trended closer to 30 days recently.
The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Merck’s (NYSE:MRK) Recarbio (imipenem/cilastatin/relebactam) for the treatment of Gram-negative infections in adults with limited treatment options.
The anti-infective will be available as a 500 mg/500 mg/250 mg powder for solution for infusion.
A final decision from the European Commission usually takes ~60 days but has trended closer to 30 days recently.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.